A phase 1 trial of an anti-RSPO3 antibody in patients with metastatic colorectal cancer was associated with partial responses in some patients, although this was not clearly associated with baseline RSPO3 expression [86]. Here, RSPO3 is linked to metastatic colorectal cancer.